Literature DB >> 8800342

Multiple sclerosis and chronic inflammatory diseases. A case-control study.

R Midgard1, M Grønning, T Riise, G Kvåle, H Nyland.   

Abstract

INTRODUCTION: Disease associations may provide useful etiological leads in relation to diseases of unknown cause.
MATERIAL AND METHODS: We conducted a hospital-based case-control study of 155 MS patients and 200 controls in Hordaland County, Norway to investigate the possible association between MS and autoimmune diseases.
RESULTS: The MS patients had a statistically significant more frequent coexistence of rheumatoid arthritis, psoriasis, and goitre when compared to the controls (OR = 2.96; 95% CI 1.23-7.66). This difference persisted when analysing the definite MS cases separately (OR = 2.90; 95% CI 1.10-7.96). The familial occurrence of chronic inflammatory diseases was not significantly different in cases and controls. A significant increased risk to develop MS occurred in first degree relatives of MS patients (OR = 12.58; 95% CI 1.73-552).
CONCLUSION: Acknowledging the low figures, the uncertain estimates with large confidence intervals, and thus the obvious role of chance in this study, the results might indicate that a generalized, genetically controlled problem of the immune system could result in aggregates of the reported diseases, all of which are partly characterized by aberrations of the immune system.

Entities:  

Mesh:

Year:  1996        PMID: 8800342     DOI: 10.1111/j.1600-0404.1996.tb00004.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  22 in total

1.  Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously.

Authors:  L R Zakka; D B Keskin; P Reche; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

2.  Epidemiology of autoimmune diseases in Denmark.

Authors:  William W Eaton; Noel R Rose; Amanda Kalaydjian; Marianne G Pedersen; Preben Bo Mortensen
Journal:  J Autoimmun       Date:  2007-06-19       Impact factor: 7.094

3.  Visual evoked potentials in patients with psoriasis vulgaris.

Authors:  A Grzybowski; G Grzybowski; A Druzdz; R Zaba
Journal:  Doc Ophthalmol       Date:  2001-11       Impact factor: 2.379

4.  Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy.

Authors:  Alice Laroni; Massimiliano Calabrese; Paola Perini; Maria Paola Albergoni; Federica Ranzato; Michela Tiberio; Leontino Battistin; Paolo Gallo
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

Review 5.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 6.  Neurological adverse events associated with anti-tumor necrosis factor α treatment.

Authors:  Antonio G Tristano
Journal:  J Neurol       Date:  2010-05-22       Impact factor: 4.849

Review 7.  Familial autoimmunity and the idiopathic inflammatory myopathies.

Authors:  E A Shamim; F W Miller
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 8.  Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis.

Authors:  Ruth Dobson; Gavin Giovannoni
Journal:  J Neurol       Date:  2013-01-12       Impact factor: 4.849

Review 9.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

10.  Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy.

Authors:  Alexander Winkelmann; Robert Patejdl; Sabine Wagner; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.